Medscape8 天
Unlabeled Uses of Factor VIIa (Recombinant) in Pediatric Patients
Summary. Factor VIIa (recombinant) is currently approved for the treatment and prevention of bleeding in patients with hemophilia A or B and inhibitors of coagulation factors, acquired hemophilia ...
hemophilianewstoday12 天
FDA approves Alhemo for hemophilia A or B with inhibitors
The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...